Literature DB >> 637706

Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations.

M A Block, C E Jackson, A H Tashjian.   

Abstract

Following operation for medullary thyroid carcinoma, elevated serum calcitonin levels were present in 18 patients who had no clinically evident residual tumor. In eight of these patients, additional operations have been performed to achieve an appropriate thyroidectomy and cervical lymph node dissection. In six of these eight, elevated serum calcitonin concentrations persist. Extensive clinical examinations failed to identify a metastatic focus of carcinoma. Serum calcitonin concentrations have remained relatively stable for up to six years (average, 3.9 years) of observations in 12 patients after initial or only operations performed from one to 13 years (average 7.3 years) previously. This suggests that microscopic metastases of this carcinoma can remain relatively dormant for years. The management of medullary thyroid carcinoma requires initially adequate cervical operations, periodic serum calcitonin measurements postoperatively, reoperation if adequate neck surgery has not been performed and if serum calcitonin levels remain elevated and only periodic reevaluation for other asymptomatic patients with persistently elevated concentrations of serum calcitonin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 637706     DOI: 10.1001/archsurg.1978.01370160026003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  12 in total

1.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 2.  Multiple endocrine neoplasia.

Authors:  R A Decker; S A Wells
Journal:  Jpn J Surg       Date:  1989-11

Review 3.  Mucosal neuromata syndrome (MEN type IIb (III)).

Authors:  J P Fryns; K Chrzanowska
Journal:  J Med Genet       Date:  1988-10       Impact factor: 6.318

4.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

5.  Improved results of cervical reoperation for medullary thyroid carcinoma.

Authors:  J F Moley; W G Dilley; M K DeBenedetti
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

6.  Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.

Authors:  Prateek Kumar Mehrotra; Anjali Mishra; Saroj Kanta Mishra; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

7.  99mTc-phosphonates for imaging of amyloid in C-cell carcinoma.

Authors:  E Reuter; N Bethge; M Matthes; K Koppenhagen
Journal:  Eur J Nucl Med       Date:  1983

8.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 9.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B).

Authors:  K Frank; F Raue; J Gottswinter; U Heinrich; H Meybier; R Ziegler
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.